Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA

Liang Wang, Jeremiah A. Aakre, Ruoxiang Jiang, Randolph Stuart Marks, Yanhong Wu, Jun Chen, Stephen N Thibodeau, V. Shane Pankratz, Ping Yang

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

INTRODUCTION:: Small cell lung cancer (SCLC) is the most aggressive form of lung malignancy. METHODS:: To identify and validate potential DNA methylation markers for risk assessment and disease detection, we examined peripheral blood leukocyte DNA specimens for methylation differences between SCLC cases and controls. We tested 1505 CpG sites using the Illumina Beadchip assay and validated 9 CpG sites using pyrosequencing technology. RESULTS:: In 44 matched SCLC case-control pairs, we identified significant differences at 62 CpG sites (false discovery rate ≤0.05) in 52 independent genes. Of those, we further determined 43 sites in 36 genes with a mean methylation level difference greater than 0.03 between the cases and controls. We then selected and validated 9 CpG sites for methylation differences in an independent set of 138 matched case-control pairs. The 9 validated CpG sites predicted a higher risk for cases than controls in 85.8% of all pairs of cases and controls, and 2 (in genes CSF3R and ERCC1) jointly contributed most of the discriminating ability. CONCLUSIONS:: Our replicated results demonstrated feasibility of applying large-scale methylation arrays for biomarker discovery and subsequent validation in peripheral blood DNA. The CpG sites identified in this study may potentially assist in risk prediction and diagnosis of SCLC.

Original languageEnglish (US)
Pages (from-to)778-785
Number of pages8
JournalJournal of Thoracic Oncology
Volume5
Issue number6
DOIs
StatePublished - Jun 2010

Fingerprint

Small Cell Lung Carcinoma
Methylation
Leukocytes
DNA
DNA Methylation
Genes
Genetic Markers
Biomarkers
Technology
Lung
Neoplasms

Keywords

  • Biomarker
  • Leukocyte
  • Methylation
  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA. / Wang, Liang; Aakre, Jeremiah A.; Jiang, Ruoxiang; Marks, Randolph Stuart; Wu, Yanhong; Chen, Jun; Thibodeau, Stephen N; Pankratz, V. Shane; Yang, Ping.

In: Journal of Thoracic Oncology, Vol. 5, No. 6, 06.2010, p. 778-785.

Research output: Contribution to journalArticle

Wang, Liang ; Aakre, Jeremiah A. ; Jiang, Ruoxiang ; Marks, Randolph Stuart ; Wu, Yanhong ; Chen, Jun ; Thibodeau, Stephen N ; Pankratz, V. Shane ; Yang, Ping. / Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA. In: Journal of Thoracic Oncology. 2010 ; Vol. 5, No. 6. pp. 778-785.
@article{f23c10d68daa4bd8b900aa83f3a86805,
title = "Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA",
abstract = "INTRODUCTION:: Small cell lung cancer (SCLC) is the most aggressive form of lung malignancy. METHODS:: To identify and validate potential DNA methylation markers for risk assessment and disease detection, we examined peripheral blood leukocyte DNA specimens for methylation differences between SCLC cases and controls. We tested 1505 CpG sites using the Illumina Beadchip assay and validated 9 CpG sites using pyrosequencing technology. RESULTS:: In 44 matched SCLC case-control pairs, we identified significant differences at 62 CpG sites (false discovery rate ≤0.05) in 52 independent genes. Of those, we further determined 43 sites in 36 genes with a mean methylation level difference greater than 0.03 between the cases and controls. We then selected and validated 9 CpG sites for methylation differences in an independent set of 138 matched case-control pairs. The 9 validated CpG sites predicted a higher risk for cases than controls in 85.8{\%} of all pairs of cases and controls, and 2 (in genes CSF3R and ERCC1) jointly contributed most of the discriminating ability. CONCLUSIONS:: Our replicated results demonstrated feasibility of applying large-scale methylation arrays for biomarker discovery and subsequent validation in peripheral blood DNA. The CpG sites identified in this study may potentially assist in risk prediction and diagnosis of SCLC.",
keywords = "Biomarker, Leukocyte, Methylation, Small cell lung cancer",
author = "Liang Wang and Aakre, {Jeremiah A.} and Ruoxiang Jiang and Marks, {Randolph Stuart} and Yanhong Wu and Jun Chen and Thibodeau, {Stephen N} and Pankratz, {V. Shane} and Ping Yang",
year = "2010",
month = "6",
doi = "10.1097/JTO.0b013e3181d6e0b3",
language = "English (US)",
volume = "5",
pages = "778--785",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "6",

}

TY - JOUR

T1 - Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA

AU - Wang, Liang

AU - Aakre, Jeremiah A.

AU - Jiang, Ruoxiang

AU - Marks, Randolph Stuart

AU - Wu, Yanhong

AU - Chen, Jun

AU - Thibodeau, Stephen N

AU - Pankratz, V. Shane

AU - Yang, Ping

PY - 2010/6

Y1 - 2010/6

N2 - INTRODUCTION:: Small cell lung cancer (SCLC) is the most aggressive form of lung malignancy. METHODS:: To identify and validate potential DNA methylation markers for risk assessment and disease detection, we examined peripheral blood leukocyte DNA specimens for methylation differences between SCLC cases and controls. We tested 1505 CpG sites using the Illumina Beadchip assay and validated 9 CpG sites using pyrosequencing technology. RESULTS:: In 44 matched SCLC case-control pairs, we identified significant differences at 62 CpG sites (false discovery rate ≤0.05) in 52 independent genes. Of those, we further determined 43 sites in 36 genes with a mean methylation level difference greater than 0.03 between the cases and controls. We then selected and validated 9 CpG sites for methylation differences in an independent set of 138 matched case-control pairs. The 9 validated CpG sites predicted a higher risk for cases than controls in 85.8% of all pairs of cases and controls, and 2 (in genes CSF3R and ERCC1) jointly contributed most of the discriminating ability. CONCLUSIONS:: Our replicated results demonstrated feasibility of applying large-scale methylation arrays for biomarker discovery and subsequent validation in peripheral blood DNA. The CpG sites identified in this study may potentially assist in risk prediction and diagnosis of SCLC.

AB - INTRODUCTION:: Small cell lung cancer (SCLC) is the most aggressive form of lung malignancy. METHODS:: To identify and validate potential DNA methylation markers for risk assessment and disease detection, we examined peripheral blood leukocyte DNA specimens for methylation differences between SCLC cases and controls. We tested 1505 CpG sites using the Illumina Beadchip assay and validated 9 CpG sites using pyrosequencing technology. RESULTS:: In 44 matched SCLC case-control pairs, we identified significant differences at 62 CpG sites (false discovery rate ≤0.05) in 52 independent genes. Of those, we further determined 43 sites in 36 genes with a mean methylation level difference greater than 0.03 between the cases and controls. We then selected and validated 9 CpG sites for methylation differences in an independent set of 138 matched case-control pairs. The 9 validated CpG sites predicted a higher risk for cases than controls in 85.8% of all pairs of cases and controls, and 2 (in genes CSF3R and ERCC1) jointly contributed most of the discriminating ability. CONCLUSIONS:: Our replicated results demonstrated feasibility of applying large-scale methylation arrays for biomarker discovery and subsequent validation in peripheral blood DNA. The CpG sites identified in this study may potentially assist in risk prediction and diagnosis of SCLC.

KW - Biomarker

KW - Leukocyte

KW - Methylation

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=77953138943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953138943&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e3181d6e0b3

DO - 10.1097/JTO.0b013e3181d6e0b3

M3 - Article

VL - 5

SP - 778

EP - 785

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 6

ER -